969 related articles for article (PubMed ID: 30826934)
21. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
[TBL] [Abstract][Full Text] [Related]
22. Arnicolide D Inhibits Triple Negative Breast Cancer Cell Proliferation by Suppression of Akt/mTOR and STAT3 Signaling Pathways.
Qu Z; Lin Y; Mok DK; Bian Q; Tai WC; Chen S
Int J Med Sci; 2020; 17(11):1482-1490. PubMed ID: 32669950
[TBL] [Abstract][Full Text] [Related]
23. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
[TBL] [Abstract][Full Text] [Related]
24. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of triple negative breast cancer cells with combination of mTOR1/2 inhibitor AZD8055 and MEK1/2 inhibitor PD0325901].
Nan XY; Wu Y; Zhang LH; Yang ZJ
Yao Xue Xue Bao; 2016 Oct; 51(10):1551-7. PubMed ID: 29932599
[TBL] [Abstract][Full Text] [Related]
26. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
[TBL] [Abstract][Full Text] [Related]
27. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
29. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
30. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
Deng S; Krutilina RI; Wang Q; Lin Z; Parke DN; Playa HC; Chen H; Miller DD; Seagroves TN; Li W
Mol Cancer Ther; 2020 Feb; 19(2):348-363. PubMed ID: 31645441
[TBL] [Abstract][Full Text] [Related]
31. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
[TBL] [Abstract][Full Text] [Related]
32. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
33. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
[No Abstract] [Full Text] [Related]
34. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Yamamoto T; Kanaya N; Somlo G; Chen S
Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
36. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
37. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
39. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
40. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
Gampa G; Kim M; Cook-Rostie N; Laramy JK; Sarkaria JN; Paradiso L; DePalatis L; Elmquist WF
Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
